Literature DB >> 9397878

Risk assessment and risk-based programs of prevention in various settings.

B J Braden1, N Bergstrom.   

Abstract

An assortment of screening tools exist to estimate risk for pressure ulcer development. The Braden Scale has undergone testing in several settings which guide users in answering the following questions: Who should assess risk? Does cut-off score differ by setting? Does timing of assessment vary by setting? Is formal risk assessment necessary? How does risk assessment fit into a program of prevention? Based on these studies, RNs are able to use the Braden Scale more reliably than Nurse Aides and LPNs. While the Braden Scale does not replace clinical judgement, its use will help caregivers of all levels to identify at risk patients and intervene for specific risk factors. Generally, all patients should be assessed upon admission and 24 to 48 hours later, followed by ongoing assessment. A formal risk-based program is effective in both reducing the incidence of pressure ulcers and the costs associated with prevention. Protocols can be developed to address each level of risk, with each level requiring more aggressive preventive modalities. Some investigators have also tied interventions to specific subscale scores. It is important that risk assessment and risk-based protocols such as the Braden Scale become a standard of practice in all healthcare settings.

Entities:  

Mesh:

Year:  1996        PMID: 9397878

Source DB:  PubMed          Journal:  Ostomy Wound Manage        ISSN: 0889-5899            Impact factor:   2.629


  2 in total

1.  Predicting the Incidence of Pressure Ulcers in the Intensive Care Unit Using Machine Learning.

Authors:  Eric M Cramer; Martin G Seneviratne; Husham Sharifi; Alp Ozturk; Tina Hernandez-Boussard
Journal:  EGEMS (Wash DC)       Date:  2019-09-05

2.  Establishment and Application of Pressure Injury Assessment Module in Operating Room Based on Information Management System.

Authors:  Fangfang Zhou; Zheng Wu; Ying Yu; Lili Xu
Journal:  J Healthc Eng       Date:  2022-01-10       Impact factor: 2.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.